Launched in 2025, the program operates through a network of 15 clinics across the United States. It functions under the ACT for ALS initiative, with backing from the National Institute of Neurological Disorders and Stroke. By prioritizing patients who lack other disease-modifying treatment options, the program aims to bridge the gap between experimental research and clinical reality.

Participants currently enrolled will maintain their treatment protocols through early 2027. Following the final follow-up, WideTrial plans to analyze the collected data to inform future scientific publications. Given the rapid uptake of this cohort, the company is already evaluating new expansion opportunities and expects to launch at least one additional large-scale program in 2027.